Secondary Trading Following Cancellation

Tissue Regenix Group PLC

07 January 2026

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Group', or the 'Company')

Secondary Trading Following Cancellation

Tissue Regenix Group plc, the regenerative medical devices company,  announces details of the secondary market trading facility that will be in place following the cancellation of the admission to trading on AIM of its ordinary shares ("Cancellation").

As previously announced, following approval by shareholders at the General Meeting held on 22 December 2025, the Cancellation will take effect from 7.00 a.m. on 7 January 2026.

Following the Cancellation, the Company has appointed Asset Match to facilitate trading in the Ordinary Shares. Asset Match, a firm authorised and regulated by the Financial Conduct Authority ((FRN 579310), will operate an electronic off-market dealing facility for the Ordinary Shares. This facility will allow existing holders of ordinary shares in the Company ("Shareholders") and new investors to trade ordinary shares by matching buyers and sellers through periodic auctions.

New investors and existing Shareholders are encouraged to register on www.assetmatch.com and add Tissue Regenix to their 'Watchlist' to continue to receive Company updates and auction/price information. Please note the Tissue Regenix page will go live on Asset Match on 7 January 2026.

The Asset Match trading facility operates under its own code of practice which governs the behaviour of participants and the running of the periodic auctions. Asset Match operates an open auction system where volumes of bids and offers at different prices are displayed on its website together with the closing date of the auction. At the end of each auction period, Asset Match passes this information through a non-discretionary algorithm that determines a "market-derived" share price based on supply and demand and allocates transactions accordingly. Bids and offers may be made and withdrawn at any time before the closing date of each auction.

Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. Shareholders wishing to trade shares through Asset Match must do so through a stockbroker. A comprehensive list of stockbrokers who have signed up to access the Asset Match platform is available on request by emailing [e-mail].

Full details will be made available to Shareholders on the Company's website at www.tissueregenix.com and directly by letter or e-mail (where appropriate). Shareholders may contact Asset Match in relation to any queries regarding trading via the secondary market trading facility by emailing [e-mail].

For more information, please contact:

Tissue Regenix Group plc
Jay LeCoque, Executive Chairman		via Walbrook PR
Asset Match Limited		[phone]
Walbrook PR (Financial PR and IR)	Tel: [phone] or [e-mail]
Alice Woodings / Paul McManus		Mob: [phone]

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 

END